SCHEMBL29728687

SCHEMBL29728687

CCCCCCCCCCCCCCCC(=O)C(OP(=O)(O)OC[C@H](O)CO)(C(=O)CCCCCCCCCCCCCCC)C(O)CO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
DUSP3 P51452 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.47
SELP P16109 1/20 0.46
LPAR1 Q92633 6/20 0.45
LPAR4 Q99677 3/20 0.45
LPAR5 Q9H1C0 3/20 0.45
LPAR2 Q9HBW0 3/20 0.45
LPAR3 Q9UBY5 3/20 0.45
ENPP2 Q13822 3/20 0.45
LPAR6 P43657 2/20 0.45
P2RY10 O00398 5/20 0.44
GPR174 Q9BXC1 5/20 0.44
GPR34 Q9UPC5 2/20 0.44
GPR55 Q9Y2T6 1/20 0.43
DGKA P23743 1/20 0.41
CES2 O00748 1/20 0.40
TRPV1 Q8NER1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28207261 1.00 KDM4E (0.47) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL30063078 1.00 KDM4E (0.47) KDM4EDUSP3MEN1KMT2ALMNA
SCHEMBL16294197 0.86 P2RY10 (0.56) P2RY10GPR174GPR34
SCHEMBL162609 0.86 P2RY10 (0.56) P2RY10GPR174GPR34
SCHEMBL16293534 0.86 P2RY10 (0.56) P2RY10GPR174GPR34
SCHEMBL9952582 0.86 P2RY10 (0.56) P2RY10GPR174GPR34
SCHEMBL3963403 0.84 PLA2G2C (0.43) LPAR1LPAR4LPAR5LPAR2LPAR3
SCHEMBL17144721 0.84 PLA2G2C (0.43) LPAR1LPAR4LPAR5LPAR2LPAR3
SCHEMBL19410782 0.84 PLA2G2C (0.43) LPAR1LPAR4LPAR5LPAR2LPAR3
SCHEMBL226745 0.84 PLA2G2C (0.43) LPAR1LPAR4LPAR5LPAR2LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241246-A1 NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM ADEIRA PHARMA, LLC 2023-08-03 US disclosed
EP-4031127-A1 NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM Adeira Pharma, LLC (US) 2022-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241246-A1 NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM HPN, ABCB1, NPPA KDM4E 4586/4885DUSP3 711/4885MEN1 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.